Non-Current Assets
Deferred Tax Assets
Vertex Pharmaceuticals Deferred Tax Assets increased by 1.7% to $2.95B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.9%, from $2.54B to $2.95B. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets shows an upward trend with a 26.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ4 2018
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase may indicate past operating losses or tax credits that provide a future buffer, while a decrease suggests the utilization of these benefits to offset tax liabilities.
Detailed definition
This represents the future tax benefits that the company expects to realize due to temporary differences between the fin...
Peer comparison
Standard across all industries; levels depend heavily on the company's historical profitability and tax jurisdiction profile.
Metric ID:
non_current_assets_deferred_income_tax_assets_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $952.81M | $933.84M | $934.50M | $945.50M | $1.14B | $1.16B | $1.25B | $1.36B | $1.54B | $1.73B | $1.81B | $1.96B | $2.19B | $2.31B | $2.33B | $2.54B | $2.71B | $2.94B | $2.90B | $2.95B |
| QoQ Change | — | -2.0% | +0.1% | +1.2% | +21.0% | +1.7% | +7.2% | +9.1% | +13.1% | +12.4% | +4.8% | +8.3% | +11.3% | +5.6% | +1.0% | +9.1% | +6.6% | +8.3% | -1.3% | +1.7% |
| YoY Change | — | — | — | — | +20.0% | +24.5% | +33.4% | +43.8% | +34.5% | +48.7% | +45.3% | +44.3% | +42.1% | +33.5% | +28.6% | +29.6% | +24.1% | +27.2% | +24.3% | +15.9% |
Range$933.84M – $2.95B
CAGR+26.8%
Avg YoY Growth+32.5%
Median YoY Growth+31.5%
Deferred Tax Assets at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's deferred tax assets?
- Vertex Pharmaceuticals (VRTX) reported deferred tax assets of $2.95B in Q1 2026.
- How has Vertex Pharmaceuticals's deferred tax assets changed year-over-year?
- Vertex Pharmaceuticals's deferred tax assets increased by 15.9% year-over-year, from $2.54B to $2.95B.
- What is the long-term trend for Vertex Pharmaceuticals's deferred tax assets?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's deferred tax assets has grown at a 26.8% compound annual growth rate (CAGR), from $882.80M to $2.90B.
- What does deferred tax assets mean?
- Future tax savings the company expects to realize based on past financial activities.